A comparison of the activity of the angiotensin converting enzyme inhibitors SQ 14 225, SA 446, and MK 421.
D015097:3-Mercaptopropionic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D000803:Angiotensin I / Q000037:antagonists & inhibitors; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology*; D004151:Dipeptides / Q000494:pharmacology*; D004656:Enalapril; D005260:Female; D006973:Hypertension / Q000503:physiopathology; D008168:Lung / Q000201:enzymology; D008297:Male; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds; D053778:Thiazolidines
D000806:Angiotensin-Converting Enzyme Inhibitors; D004151:Dipeptides; D013438:Sulfhydryl Compounds; D053778:Thiazolidines; D000804:Angiotensin II; D004656:Enalapril; D000803:Angiotensin I; D011392:Proline; D002216:Captopril; D015097:3-Mercaptopropionic Acid; C033437:rentiapril